Visual Field Defect after Taking Atorvastatin/Ezetimibe, a Case Study
10.24304/kjcp.2019.29.2.133
- Author:
Jiyoon KIM
1
;
Kyunggyu LEE
;
Junyoung KIM
;
Jung Min LEE
;
Na Young KIM
;
Mo Se LEE
;
Eunhee JI
Author Information
1. College of Pharmacy, Gachon University, Incheon 21936, Republic of Korea. ehji@gachon.ac.kr
- Publication Type:Case Report
- Keywords:
Atorvastatin;
visual field defect;
adverse drug reaction;
causality assessment
- MeSH:
Aged;
Atorvastatin Calcium;
Cataract;
Cholesterol;
Diplopia;
Drug-Related Side Effects and Adverse Reactions;
Dyslipidemias;
Ezetimibe;
Female;
Global Health;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Korea;
Muscular Diseases;
Oxidative Stress;
Pharmacies;
Vision Disorders;
Visual Fields
- From:Korean Journal of Clinical Pharmacy
2019;29(2):133-137
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Atorvastatin is one of the most widely prescribed medications for dyslipidemia treatment. In Korea, post combined therapy with ezetimibe, a 73-year-old woman was reported by a community pharmacy to have experienced visual field defect, which recovered after drug discontinuation. She had never experienced this symptom before, and several studies have reported an association between use of statins and visual disorders such as blurred vision, diplopia, and cataract. Blockage of cholesterol accumulation, oxidative stress, or myopathy is expected to be a cause of this symptom. Naranjo scale, Korean causality assessment algorithm (Ver.2), and World Health Organization-Uppsala Monitoring Center (WHO-UMC) criteria were the three tools used to determine causality between the visual disorder and atorvastatin. The results represent ‘probable’, ‘certain’, and ‘probable/likely’ causality, respectively. Our results, in combination with a review of literature, indicate that ocular adverse effects are highly likely related to atorvastatin.
